Upgrades by major financial institutions like Wells Fargo typically lead to positive short-term price movements for stocks. The substantial increase in the price target from $21 to $45 reflects a strong confidence in Tandem Diabetes Care's future performance, likely influencing investor sentiment and potentially driving the stock price up in the short term.